Klebsiella Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Klebsiella Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Klebsiella infections are caused by bacteria of the genus Klebsiella, with K. pneumoniae being the most common species associated with human infections. These bacteria are part of the normal flora in the human digestive tract and respiratory system but can cause various infections, especially in individuals with weakened immune systems or underlying health conditions.
Klebsiella infections can manifest in different parts of the body, leading to various clinical presentations. K. pneumoniae is notorious for causing a severe form of pneumonia, particularly in hospitalized patients, elderly individuals, or those with chronic lung diseases. Symptoms include high fever, coughing, difficulty breathing, and in some cases, coughing up blood.
The Klebsiella Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Klebsiella Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Klebsiella Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Klebsiella Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 74 molecules, with 62 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Klebsiella Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Klebsiella Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Klebsiella Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ABAC Therapeutics SAAbGenics Life Sciences Pvt Ltd
AEON Medix Inc
AJK Biopharmaceutical LLC
Akthelia Pharmaceuticals Ltd
Alterity Therapeutics Ltd
Armata Pharmaceuticals Inc
BB200 LLC
Bioversys AG
Celdara Medical LLC
Centivax Inc
CHO Pharma Inc
Clarametyx Biosciences Inc
ContraFect Corp
Development Center for Biotechnology
Dong-A ST Co Ltd
EffectorBio Inc
Entasis Therapeutics Holdings Inc
Evoq Nano Inc
F. Hoffmann-La Roche Ltd
Fedora Pharmaceuticals Inc
Forge Therapeutics Inc
GSK plc
Idorsia Pharmaceutical Ltd
Immunethep SA
Institute for Development Research
Inventprise LLC
King's College London
LimmaTech Biologics AG
Linnaeus Bioscience Inc
Meiji Seika Pharma Co Ltd
Melinta Therapeutics LLC
Microbiotix Inc
Mikrobiomik Healthcare Company SL
Nektr Technologies Ltd
Neoculi Pty Ltd
Nosopharm SAS
Omniose
Pedanius Therapeutics Ltd
Peptilogics Inc
PHAXIAM Therapeutics SA
Phico Therapeutics Ltd
Planet Biotechnology Inc
Pylum Biosciences Inc
Recce Pharmaceuticals Ltd
Redx Pharma Plc
RemAb Therapeutics SL
Seres Therapeutics Inc
Shionogi & Co Ltd
Spero Therapeutics Inc
Spexis AG
Stony Brook University
Summit Therapeutics Inc
Syntiron LLC
Taisho Pharmaceutical Holdings Co Ltd
Telum Therapeutics SL
The Lundquist Institute
The National Institute of Allergy and Infectious Diseases
Tulane University
University College Dublin
University of Bern
University of Pittsburgh
University Pompeu Fabra
Venus Medicine Research Centre
Wayne State University
Xellia Pharmaceuticals ApS
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Klebsiella Infections reports